FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated…

Recurrent Energy begins operation of 127 MW solar project in Louisiana

Recurrent Energy, a subsidiary of Canadian Solar Inc. and a global developer, owner, and operator of…

UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Inva

UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial…

Safety First: Buy Preferred Stocks For Big Recurrent Income

This article was written by Follow Rida Morwa is a former investment and commercial Banker, with…

My Resolutions For 2025: Big And Passive Recurrent Income

This article was written by Follow Rida Morwa is a former investment and commercial Banker, with…

My Retirement Goal: Live Off Passive Recurrent Income

This article was written by Follow Rida Morwa is a former investment and commercial Banker, with…